Overview
Baxerna is developing a bacterial vaccine pipeline using mRNA technology against three facultative intracellular pathogens. The company uses immunopeptidomics to discover bacterial antigens, develops novel mRNA formulations, and integrates innovative production methods for local manufacturing and cost optimization.
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.